コンテンツへスキップ
Merck

HCKP1-11K

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel

Configurable Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

ログインで組織・契約価格をご覧ください。

この商品について

NACRES:
NA.84
UNSPSC Code:
12161503


製品名

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel,

description

Configurable Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

cell culture supernatant(s)
plasma

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 17 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2)

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • High-Plex Immune Profiling: Simultaneously quantify 17 key checkpoint proteins (e.g., PD-1, CTLA-4, LAG-3, TIM-3) in a single run, streamlining analysis of co-stimulatory and co-inhibitory pathways.
  • Luminex®xMAP® Technology: Leverage bead-based multiplexing for high-throughput, reproducible detection with minimal sample volume (25 μL/well).
  • Configurable Panels: Select specific analytes from the 17-plex panel to tailor assays to your research focus, optimizing cost and efficiency.
  • Accelerate Translational Research: Unlock insights into immune checkpoint dynamics in cancer, autoimmunity, and immunotherapy efficacy.
  • Biomarker Discovery Powerhouse: Identify putative biomarkers (e.g., soluble PD-L1, CTLA-4) for patient stratification or treatment monitoring.

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?


signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

保管分類

10 - Combustible liquids

wgk

WGK 3


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Please refer to KIT Component information

pdsc

Please refer to KIT Component information

prtr

Please refer to KIT Component information

fsl

Please refer to KIT Component information

ishl_indicated

Please refer to KIT Component information

ishl_notified

Please refer to KIT Component information

cart

キットコンポーネントの情報を参照してください

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする